[go: up one dir, main page]

MX2009013115A - Derivados de prolinamida como antagonistas de nk3. - Google Patents

Derivados de prolinamida como antagonistas de nk3.

Info

Publication number
MX2009013115A
MX2009013115A MX2009013115A MX2009013115A MX2009013115A MX 2009013115 A MX2009013115 A MX 2009013115A MX 2009013115 A MX2009013115 A MX 2009013115A MX 2009013115 A MX2009013115 A MX 2009013115A MX 2009013115 A MX2009013115 A MX 2009013115A
Authority
MX
Mexico
Prior art keywords
sup
lower alkyl
hydrogen
halogen
substituted
Prior art date
Application number
MX2009013115A
Other languages
English (en)
Inventor
Hasane Ratni
Henner Knust
Bo Han
Matthias Nettekoven
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009013115A publication Critical patent/MX2009013115A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula (I) en donde R1 es hidrógeno, halógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior, o alcoxi inferior sustituido por halógeno; R2 es hidrógeno o alquilo inferior; R3, R4 forman conjuntamente con el átomo de N al cual se unen un grupo heterocíclico no aromático, seleccionado de R5 es hidrógeno o halógeno; R6 es fenilo, insustituido o sustituido por ciano, halógeno, alquilo inferior, alcoxi inferior, CF3, -(CH2)20-alquilo inferior, C(O)-alquilo inferior o C(O)O-alquilo inferior, o es piridinilo, insustituido o sustituido por CF3, o es -C(O)-fenilo; R7 es hidrógeno o alquilo inferior; R8 es fenilo, alquilo inferior o -C(O)O-alquilo inferior; R9 es hidrógeno o S(O)2-alquilo inferior; R10 es hidrógeno o cicloalquilo; X es -CH2- o -C(O)-; p es 1 o 2; n es 1, 2 o 3; o es 1 o 2; o a una sal de adición de ácido farmacéuticamente adecuada del mismo, los cuales son altos antagonistas del receptor de NK-3 potenciales para el tratamiento de depresión, dolor, psicosis, enfermedad de Parkinson, esquizofrenia, ansiedad y trastorno de hiperactividad por déficit de atención (ADHD).
MX2009013115A 2007-06-07 2008-05-29 Derivados de prolinamida como antagonistas de nk3. MX2009013115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109781 2007-06-07
PCT/EP2008/056589 WO2008148689A1 (en) 2007-06-07 2008-05-29 Prolinamide derivatives as nk3 antagonists

Publications (1)

Publication Number Publication Date
MX2009013115A true MX2009013115A (es) 2010-01-15

Family

ID=39639487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013115A MX2009013115A (es) 2007-06-07 2008-05-29 Derivados de prolinamida como antagonistas de nk3.

Country Status (14)

Country Link
US (1) US7528136B2 (es)
EP (1) EP2155672B1 (es)
JP (1) JP2010529069A (es)
KR (1) KR101163292B1 (es)
CN (1) CN101679241B (es)
AT (1) ATE486058T1 (es)
AU (1) AU2008258665B2 (es)
BR (1) BRPI0812447A2 (es)
CA (1) CA2689560A1 (es)
DE (1) DE602008003221D1 (es)
ES (1) ES2351378T3 (es)
IL (1) IL202236A0 (es)
MX (1) MX2009013115A (es)
WO (1) WO2008148689A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126030A1 (ja) * 2009-04-28 2010-11-04 中外製薬株式会社 スピロイミダゾロン誘導体
US8314250B2 (en) 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
US8618303B2 (en) * 2011-01-07 2013-12-31 Hoffmann-La Roche Inc. Pyrrolidine derivatives
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
US9090559B2 (en) 2012-02-24 2015-07-28 Hoffmann-La Roche Inc. Antiviral compounds
NO2930176T3 (es) 2012-12-10 2018-07-07
RU2701168C2 (ru) 2014-06-09 2019-09-25 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция, содержащая производные гидантоина
CN105153005A (zh) * 2015-08-05 2015-12-16 上海瑞博化学有限公司 一种4-羰基-脯氨酸衍生物的制备方法
US11491136B2 (en) 2017-02-14 2022-11-08 Research Triangle Institute Proline-based neuropeptide FF receptor modulators
KR102453438B1 (ko) 2020-06-15 2022-10-12 주식회사 한중엔시에스 리저버 일체형 진공 펌프

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169731A (zh) * 1994-12-13 1998-01-07 诺瓦蒂斯有限公司 速激肽拮抗剂
JO2696B1 (en) * 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
BRPI0510951A (pt) * 2004-05-12 2007-11-20 Pfizer Prod Inc derivados de piperidina como antagonistas de nk1 e nk3

Also Published As

Publication number Publication date
DE602008003221D1 (de) 2010-12-09
ATE486058T1 (de) 2010-11-15
AU2008258665B2 (en) 2012-07-05
ES2351378T3 (es) 2011-02-03
US20080306086A1 (en) 2008-12-11
JP2010529069A (ja) 2010-08-26
EP2155672A1 (en) 2010-02-24
KR20100028629A (ko) 2010-03-12
CN101679241B (zh) 2012-06-27
IL202236A0 (en) 2010-06-16
US7528136B2 (en) 2009-05-05
BRPI0812447A2 (pt) 2014-12-02
WO2008148689A1 (en) 2008-12-11
KR101163292B1 (ko) 2012-07-05
CN101679241A (zh) 2010-03-24
EP2155672B1 (en) 2010-10-27
AU2008258665A1 (en) 2008-12-11
CA2689560A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
PH12012500951A1 (en) Substituted benzamide derivatives
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
SG195156A1 (en) Pyrazole derivatives
MX2010001080A (es) Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
MX2009009384A (es) Malonamidas como antagonistas de orexina.
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
PH12013501895A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5
ATE532780T1 (de) Chinoline und ihre therapeutische verwendung
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
JP2013526610A5 (es)
MX2012008147A (es) Derivados de pirrazolopiridina.
MX2009010727A (es) Heterociclos como antagonistas de orexina.
PH12018500247A1 (en) Ethynyl derivatives
MX2012006293A (es) Derivados de pirrolidina como antagonista del receptor nk-3.
WO2008153902A2 (en) Urotensin ii receptor antagonists
PH12012502348A1 (en) Novel spiroheterocyclic compounds as mglu5 antagonists
MX2013007411A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2009006972A (es) Derivados de espiropiperidina como antagonistas de neuroquinina 3.

Legal Events

Date Code Title Description
FG Grant or registration